Oxygen Double Bonded To A Ring Carbon Of The Cyclopentanohydrophenanthrene Ring System Patents (Class 514/177)
  • Patent number: 10295527
    Abstract: A process and system directed to a more effective, individual based treatment regimen which is built on clinical identified target biomarkers associated with gender differential responses to mesalamine, and includes one or more panels of target biomarkers that distinguishes mesalamine response differences between genders and determines the efficacy of mesalamine for patients being treated for various UC conditions and effectively identifies and validates novel drug targets for new UC therapeutics, new diagnostics and diagnostics standards for UC therapeutic strategies.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: May 21, 2019
    Inventors: Bruce Yacyshyn, Mary E. Yacyshyn
  • Patent number: 10253369
    Abstract: Provided are methods of determining whether a subject having ER+ breast cancer is expected to benefit from treatment with combination endocrine therapy and mTOR inhibitor therapy. Also provided are methods of treating a subject having ER+ breast cancer.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: April 9, 2019
    Assignee: BIOTHERANOSTICS, INC.
    Inventors: Catherine Schnabel, Yi Zhang, Mark G. Erlander
  • Patent number: 10213440
    Abstract: Formulations for oral transmucosal compositions including a synergistic combination of low doses of testosterone with an aromatase inhibitor (AI) that are combined with transmucosal absorption enhancers are disclosed. Oral transmucosal compositions can be for fast release or slow release, and can be administered to increase bloodstream testosterone levels and thereby reduce symptoms of testosterone deficiency. Oral transmucosal compositions include liquid dosage forms, solid dosage forms, and chewing gums. Further dosage forms include mucoadhesive thin strips, thin films, tablets, patches, and tapes, among others. Other dosage forms are: mucoadhesive liquids such as gel-forming liquids; gel-forming semisolids; and gel-forming powders, among other dosage forms that exhibit mucoadhesive properties, and provide oral transmucosal delivery of testosterone and AI.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: February 26, 2019
    Assignee: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA (PCCA)
    Inventors: Tsu-I Catherine Wang, Bruce Vincent Biundo
  • Patent number: 10022384
    Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: July 17, 2018
    Assignee: Lipocine Inc.
    Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Kumar Nachaegari, Nachiappan Chidambaram, Mahesh V. Patel
  • Patent number: 9968554
    Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: May 15, 2018
    Assignee: The University of British Columbia
    Inventors: Pieter Cullis, Marcel Bally, Marco Ciufolini, Norbert Maurer, Igor Jigaltsev
  • Patent number: 9949926
    Abstract: The present invention aims to provide an eye drop for treating macular edema. The present invention provides an eye drop for treating macular edema, which contains difluprednate as an active ingredient. The eye drop can afford effects such as improvement of visual acuity and decreased foveal retinal thickness in macular edema.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: April 24, 2018
    Assignee: YAMAGATA UNIVERSITY
    Inventors: Hidetoshi Yamashita, Teiko Yamamoto, Sakiko Goto, Sachi Abe, Eriko Kirii, Atsushi Okumura
  • Patent number: 9931349
    Abstract: This disclosure provides a novel pharmaceutical composition for delivering steroid hormones to a patient in need thereof.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: April 3, 2018
    Assignee: TherapeuticsMD, Inc.
    Inventors: Annette Shadiack, Peter H. R. Persicaner, Philip B. Inskeep, Thorsteinn Thorsteinsson, Frederick D. Sancilio, Jason D. Legassie
  • Patent number: 9895407
    Abstract: The present invention provides a disinfecting formulation useful, for example, for cleaning and disinfecting human or animal body parts, and in particular for disinfecting human hands. The disinfecting formulation comprises alcohol including ethanol; an essential oil comprising cineole, in particular eucalyptus oil; an emollient including glycerin; and other ingredients comprising piroctone olamine, acrylic acid based polymer and 2-amino-2-methyl-1-propanol. The invention also provides methods of disinfection of human and animal body parts and methods for preparing the formulation.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: February 20, 2018
    Assignee: Sunny Wipes Pty Ltd
    Inventor: Peter Lawrence Steve
  • Patent number: 9750691
    Abstract: A composition comprising an INTEROMONE® is described for the modification of undesirable or harmful stress-related behaviors or other behaviors or physiology in a variety of vertebrate species, as well as methods of using the compositions in vertebrates from a species different than the species in which the INTEROMONE® is a naturally occurring pheromone.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: September 5, 2017
    Assignee: Sergeant's Pet Care Products, Inc.
    Inventors: John McGlone, Larry Nouvel
  • Patent number: 9737609
    Abstract: The present disclosure refers to a synergistic blend of Konjac powder and Xanthan gum that is included, as a natural suspending agent, in oral pharmaceutical suspensions. Oral pharmaceutical suspensions comprising the synergistic blend are aqueous solutions. The synergistic blend, used as a suspension agent to suspend suitable active pharmaceutical ingredients (APIs), improves the stability of oral pharmaceutical suspensions, and helps in the formation of a thermo-reversible gel and shear thinning necessary to keep APIs suspended within oral pharmaceutical suspensions. The synergistic blend of Konjac powder and Xanthan gum has unique anti-flocculation properties, which improve the homogeneity of the oral pharmaceutical suspensions. Additionally, the blend provides a better texture and mouth feel.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: August 22, 2017
    Assignee: Professional Compounding Centers of America (PCCA)
    Inventors: Christine Vu, Fabiana Banov, Daniel Banov
  • Patent number: 9561239
    Abstract: A composition for use in inhibiting the binding of a Norovirus to the histo-blood group antigen on the surface of epithelia is disclosed. The composition may contain a therapeutically effective amount of a binding-inhibiting compound and a carrier and/or excipient. The compounds may competitively bind a Norovirus that has the capability of binding with the histo-blood group antigens of secretor blood type, including A, B, AB, and O blood types. The compositions may be administered to a human prior to or after infection by a Norovirus, to prevent, ameliorate, or reduce the effects of an infection.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: February 7, 2017
    Assignee: Children's Hospital Medical Center
    Inventors: Xi Jiang, Ming Tan, Xufu Zhang
  • Patent number: 9504697
    Abstract: Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: November 29, 2016
    Assignee: BESINS HEALTHCARE LUXEMBOURG SARL
    Inventors: Anne Caufriez, Georges Copinschi
  • Patent number: 9498436
    Abstract: Solutions of testosterone for oromucosal administration providing an increase in serum testosterone levels in subjects deficient in endogenous testosterone levels, and therapeutic methods for providing an increase in serum testosterone levels and methods for treating a disease or a symptom associated with deficient endogenous levels of testosterone.
    Type: Grant
    Filed: August 9, 2011
    Date of Patent: November 22, 2016
    Assignee: INNOTESTO BVBA
    Inventor: Franciscus Wilhelmus Henricus Maria Merkus
  • Patent number: 9480689
    Abstract: The present disclosure provides for compositions and methods of stimulating reproductive behavior and reproductive success and productivity in a suid, such as pigs. The composition may comprise at least one steroid hormone and a heterocyclic aromatic compound. The method comprises administering the pheromone composition to the suid for a period of time.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: November 1, 2016
    Assignee: Animal Biotech, LLC
    Inventor: John J. McGlone
  • Patent number: 9468647
    Abstract: Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: October 18, 2016
    Assignee: MISCON TRADING S.A.
    Inventor: Mirudhubashini Govindarajan
  • Patent number: 9408856
    Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 9, 2016
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Arthur G Schwartz, John R Williams
  • Patent number: 9402853
    Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 2, 2016
    Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION
    Inventors: Arthur G Schwartz, John R Williams
  • Patent number: 9375476
    Abstract: A pharmaceutical composition of botulinum toxin and an adjuvant is disclosed. The composition is formulated for topical administration to deliver a therapeutically effective dose of botulinum toxin to an area of a subject suffering from inflammation. The botulinum toxin composition reduces a symptom of inflammation without producing substantial muscle weakness. The composition may optionally contain additional anti-inflammatory agents, such as steroidal or non-steroidal agents.
    Type: Grant
    Filed: December 31, 2008
    Date of Patent: June 28, 2016
    Assignee: Botulinum Toxin Research Associates, Inc.
    Inventor: Gary E. Borodic
  • Patent number: 9365609
    Abstract: The present invention provides a process for preparing a crystalline form of halobetasol propionate, comprising the step of crystallizing halobetasol propionate from absolute ethanol or a mixture of ethanol and water, wherein the crystalline form of halobetasol propionate is characterized by an x-ray powder diffraction pattern having peaks at 10.0, 11.6, 12.9, 13.4, 14.5, 16.4, 17.6, and 23.5±0.2 degrees 2?.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: June 14, 2016
    Assignee: TARO PHARMACEUTICALS NORTH AMERICA, INC.
    Inventors: Daniella Gutman, Shimon Chernyak
  • Patent number: 9339508
    Abstract: A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3?-methoxy-pregna-5-ene-20-one (3?-methoxy-PREG).
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: May 17, 2016
    Assignee: MAPREG
    Inventors: Etienne-Emile Baulieu, Esther Fellous, Paul Robel
  • Patent number: 9322067
    Abstract: Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: April 26, 2016
    Assignee: Caris MPI, Inc.
    Inventors: Daniel D. Von Hoff, David M. Loesch, Arlet Alarcon, Robert J. Penny, Alan Wright, Matthew J. McGinniss, Ryan P. Bender, Traci Pawlowski
  • Patent number: 9320745
    Abstract: The present invention relates to the use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug, with the exception of a neuroprotective drug.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: April 26, 2016
    Assignee: TROPHOS
    Inventors: Rebecca Pruss, Bruno Buisson, Thierry Bordet
  • Patent number: 9305137
    Abstract: In one embodiment, the invention provides methods of identifying genes and genetic variants that, either alone or in combination, are important to the pathogenesis of a disease. In another embodiment, the disease is stratified by use of an immune response to disease-associated antigens. In another embodiment, the invention provides methods of identifying pathways that, either alone or in combination, are important to the pathogenesis of a disease. In another embodiment, the invention provides a method of diagnosing or predicting susceptibility to a disease in an individual by determining the presence or absence of genes and genetic variants that, either alone or in combination, are important to the pathogenesis of the disease.
    Type: Grant
    Filed: May 16, 2008
    Date of Patent: April 5, 2016
    Assignee: Cedars-Sinai Medical Center
    Inventors: Stephan R. Targan, Jerome I. Rotter, Kent D. Taylor
  • Patent number: 9278132
    Abstract: A stable ophthalmic pharmaceutical composition for relief, treatment, control, alleviation, or prevention of a pathological ocular condition of the eye comprises: (a) a first polymer, a viscosity of which changes with a change in a concentration of an electrolyte, such as a salt, when added to said first polymer; (b) a second polymer that is different from the first polymer and can modify the viscosity of the first polymer; and (c) an oil. In some embodiments, the composition further comprises a non-ionic surfactant. The composition can form a stable oil-in-water emulsion on storage, but separate into an oil phase and a water phase when applied in the eye. The emulsion can comprises an ophthalmic active pharmaceutical ingredient dissolved in the oil or water phase. The emulsion can provide enhanced stability to said active pharmaceutical ingredient.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: March 8, 2016
    Assignee: Bausch & Lomb Incorporated
    Inventors: Stephen R. Davio, Paramita Sarkar, Zora T. Marlowe, Brian J. Glass, Tammy J. Kleiber
  • Patent number: 9238072
    Abstract: This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: January 19, 2016
    Assignee: MATTERN PHARMA AG
    Inventor: Claudia Mattern
  • Patent number: 9220699
    Abstract: The present document describes a composition for sustained, targeted or sustained and targeted delivery of an active ingredient which includes a complex formed between a carboxyl substituted polymer and a lipid. The present document also describes dosage forms containing the composition, and an active ingredient, and methods of using the same for the treatment of diseases.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: December 29, 2015
    Assignee: KARICI DIAGNOSTICS INC.
    Inventors: Le Tien Canh, Mihaela Friciu, Pompilia Ispas-Szabo, Mircea Alexandru Mateescu
  • Patent number: 9084797
    Abstract: Described herein are therapeutic methods using progesterone and progesterone analogs to improve sleep quality. The methods may be particularly useful to treat subject with perturbed sleep patterns, such as subjects who suffer from mid-sleep period awakenings.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: July 21, 2015
    Assignee: BESINS HEALTHCARE LUXEMBOURG SARL
    Inventors: Anne Caufriez, Georges Copinschi
  • Publication number: 20150148323
    Abstract: Various pharmaceutical formulations are disclosed herein. For example, a pharmaceutical formulation is disclosed comprising ultra-micronized progesterone.
    Type: Application
    Filed: June 18, 2013
    Publication date: May 28, 2015
    Inventors: Janice Louise Cacace, Peter H.R. Periscaner
  • Publication number: 20150141350
    Abstract: A nanodevice composition including N-acetyl cysteine linked to a dendrimer, such as a PAMAM dendrimer or a multiarm PEG polymer, is provided. Also provided is a nanodevice for targeted delivery of a compound to a location in need of treatment. The nanodevice includes a PAMAM dendrimer or multiarm PEG polymer, linked to the compound via a disulfide bond. There is provided a nanodevice composition for localizing and delivering therapeutically active agents, the nanodevice includes a PAMAM dendrimer or multiarm PEG polymer and at least one therapeutically active agent attached to the PAMAM dendrimer or multiarm PEG polymer.
    Type: Application
    Filed: September 4, 2014
    Publication date: May 21, 2015
    Inventors: Rangaramanujam M. Kannan, Sujatha Kannan, Roberto Romero, Raghavendra S. Navath, Hui Dai, Anupa R. Menjoge
  • Publication number: 20150140127
    Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.
    Type: Application
    Filed: June 25, 2013
    Publication date: May 21, 2015
    Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
  • Publication number: 20150133382
    Abstract: The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 14, 2015
    Applicant: JUNEAU BIOSCIENCES, LLC
    Inventors: Kenneth Ward, Rakesh N. Chettier, Hans Albertsen
  • Patent number: 9029355
    Abstract: In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D50) of the particles is from about 50 nm to about 500 nm.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: May 12, 2015
    Assignee: Marinus Pharmaceuticals
    Inventors: Kenneth Shaw, Mingbao Zhang
  • Publication number: 20150111834
    Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.
    Type: Application
    Filed: September 17, 2014
    Publication date: April 23, 2015
    Applicant: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: Felice CHENG, Maggie J.M. LU, Yi-Ju KO, Min-Ying LIN, Shuen-Hsiang CHOU
  • Publication number: 20150112116
    Abstract: Provided herein are methods comprising providing a tyrosine derivative and a solid particulate material (and, optionally, melanin) and applying force to said tyrosine derivative and said solid particulate material for a time and under conditions effective to impregnate at least one of said tyrosine derivative and said solid particulate material with the other of said tyrosine derivative and said solid particulate material. The invention also provides compositions comprising at least one of a tyrosine derivative impregnated with a solid particulate material and a solid particulate material impregnated with a tyrosine derivative.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 23, 2015
    Inventor: STEVEN HOFFMAN
  • Patent number: 9011908
    Abstract: Fill materials for hydrophobic drugs, such as progesterone, and methods of making and using thereof are described herein. The fill material contains the hydrophobic drug dissolved in one or more fatty acids. The concentration of the hydrophobic drug is typically from about 7% to about 50% by weight of the fill material. The concentration of the one or more fatty acids is from about 60% to about 95% by weight of the carrier. The formulation also contains an organic acid and one or both of one or more pharmaceutically acceptable alcohols and one or more pharmaceutically acceptable mono-, di-, or triesters of medium or long chain fatty acids. The fill material can be encapsulated in a hard or soft capsule. The formulations described herein have a higher dissolution rate and faster onset of dissolution compared to micronized progesterone suspended in an oil and thus should have increased bioavailability in vivo.
    Type: Grant
    Filed: April 1, 2010
    Date of Patent: April 21, 2015
    Assignee: Banner Life Sciences LLC
    Inventors: Zhi Liu, Saujanya L. Gosangari, Dana S. Toops, Aqeel Fatmi
  • Publication number: 20150098978
    Abstract: A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissolved within an oral cavity.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke, Gerd Kobal
  • Publication number: 20150094289
    Abstract: Provided herein are small molecules that have a neuroprotective or modulatory effect in the nervous system. The small molecules provided herein modulate dopaminergic neuronal activity. Also provided herein are methods of for the prophylaxis of or preventing the progression of Parkinson's Disease (PD).
    Type: Application
    Filed: June 3, 2013
    Publication date: April 2, 2015
    Inventors: Rudolfo Gonzalez, Ibon Garitaonandia, Ruslan Semechkin
  • Publication number: 20150094288
    Abstract: A method of treating a solid tumor in a mammal by inhibiting angiogenesis, including administering to the mammal which has a solid tumor selected from the group consisting of breast carcinoma, lung carcinoma, prostate carcinoma, colon carcinoma, ovarian carcinoma, neuroblastoma, central nervous system tumor, multiform glioblastoma and melanoma; a composition including brassinosteroids of general formula (I) wherein can be a single or double bond and the configurations of carbon atoms C22 and C23 respectively linked to the substituents HO are S for both carbon atoms and a pharmaceutically acceptable additive.
    Type: Application
    Filed: December 14, 2012
    Publication date: April 2, 2015
    Applicant: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECHNICAS (CONICET)
    Inventors: Javier Alberto Ramirez, Flavia Mariana Michelini, Lydia Raquel Galagovsky, Alejandro Berra, Laura Edith Alche
  • Publication number: 20150094291
    Abstract: The invention provides a method for improving the emotional development of an infant by performing controlled exposure of the infant aged less than six months old to human fear pheromone, preferably with visual fear stimuli, so that the natural synaptic connections in the brain associated with normal fear mechanisms are stimulated and exercised. This can reduce the occurrence of mental illness later in life, in particular reduce the occurrence of schizophrenia. Advantageously the exposure to fear pheromone and visual fear stimuli is terminated and followed by comforting stimuli such as feeding, physical contact, or comforting or happy visual or audible stimuli such as laughter.
    Type: Application
    Filed: October 2, 2013
    Publication date: April 2, 2015
    Applicant: Opendot Research Co Limited
    Inventor: Derek John GOLDSMITH
  • Patent number: 8993520
    Abstract: The invention is directed to a transdermal drug delivery composition which includes at least one physiologically active agent; and at least one volatile solvent; and at least one viscosity modulating agent. The invention extends to methods of administering such a composition to a subject and treatment of subjects using the composition.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: March 31, 2015
    Assignee: Acrux DDS Pty Ltd
    Inventors: Tony Dipietro, Andrew Humberstone, Igor Gonda, Adam Watkinson, Kerrie Setiawan, Nina Wilkins
  • Publication number: 20150079189
    Abstract: In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.
    Type: Application
    Filed: September 13, 2014
    Publication date: March 19, 2015
    Applicant: Arbor Therapeutics, LLC
    Inventors: James D. McChesney, Igor Nikoulin, Steve J. Bannister, Douglas L. Rodenburg
  • Patent number: 8969327
    Abstract: The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.
    Type: Grant
    Filed: April 7, 2011
    Date of Patent: March 3, 2015
    Assignees: Emory University, The Research Foundation of State of New York, Hauptman-Woodward Medical Research Institute
    Inventors: Huw Davies, Dabashis Ghosh, Daniel Morton
  • Publication number: 20150056269
    Abstract: The present invention relates to a novel galenic form of cholesterol derivative. More particularly the invention relates to liposomes comprising at least one cholesterol derivative and compositions comprising said liposomes.
    Type: Application
    Filed: August 22, 2012
    Publication date: February 26, 2015
    Applicant: TROPHOS
    Inventors: Corinne Chaimbault, Magali Michaud, Patrick Berna, Sophie Schaller, Firas Bassissi, Simon Eastman
  • Patent number: 8962603
    Abstract: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: February 24, 2015
    Assignee: Laboratoire HRA-Pharma
    Inventors: Delphine Levy, Andre Ulmann, Henri Camille Mathe, Erin Gainer
  • Publication number: 20150050355
    Abstract: A particulate SAE-CD composition is provided. The SAE-CD composition has an advantageous combination of physical properties not found in known solid forms of SAECD. In particular, the SAE-CD composition possesses an advantageous physicochemical and morphological property profile such that it can be tailored to particular uses. The SAE-CD composition of the invention has improved flow and dissolution performance as compared to known compositions of SAE-CD.
    Type: Application
    Filed: September 17, 2014
    Publication date: February 19, 2015
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Patent number: 8957115
    Abstract: Pheromone compositions based on a combination of squalene, linoleic acid and 1-docosanol are described. The compositions are useful for behavior modification in mammals that exhibit undesirable or harmful stress-related behaviors.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: February 17, 2015
    Assignee: Sergeant's Pet Care Products, Inc.
    Inventors: Larry Nouvel, Cuong Tu Ba, Luis Rios
  • Publication number: 20150044291
    Abstract: Endometriosis, including endometriosis externa, endometrioma, adenomyosis, adenomyomas, adenomyotic nodules of the uterosacral ligaments, and endometriotic nodules, such as scar endometriosis are effectively treated by the intralesional administration, including transvaginal, endoscopic or open surgical administration including via laparotomy, of a progestogen. Compositions therefor also are provided.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 12, 2015
    Inventor: Mirudhubashini GOVINDARAJAN
  • Patent number: 8912174
    Abstract: The invention involves methods and formulations for treating or preventing rhinosinusitis, including fungus-induced rhinosinusitis in mammals. In one embodiment, the formulation of the present invention comprises a steroidal anti-inflammatory agent having a specific particle size distribution profile. The formulation may also comprise an antifungal agent, antibiotic or antiviral agent.
    Type: Grant
    Filed: September 4, 2003
    Date of Patent: December 16, 2014
    Assignee: Mylan Pharmaceuticals Inc.
    Inventor: Imtiaz Chaudry
  • Publication number: 20140349984
    Abstract: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.
    Type: Application
    Filed: January 2, 2014
    Publication date: November 27, 2014
    Applicant: EMORY UNIVERSITY
    Inventors: Stuart W. Hoffman, Arthur L. Kellermann, Donald G. Stein, David W. Wright, Douglas W. Lowery-North
  • Patent number: 8895053
    Abstract: The subject invention provides improved testosterone gel formulations.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: November 25, 2014
    Assignee: Ferring B.V.
    Inventors: Arnaud Grenier, Dario N. Carrara